Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Kazia Therapeutics Ltd ADR (KZIA)

Kazia Therapeutics Ltd ADR (KZIA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Kazia Therapeutics Ltd ADR Three International Towers Level 24 300 Barangaroo Avenue Sydney C3 2000 AUS

www.kaziatherapeutics.com Employees: 12 P: 61-2-9472-4101 F: +61 294760388

Description:

Kazia Therapeutics Limited is an oncology-focused biotechnology company. It develops anti-cancer drugs as well as provides pharmaceutical research and development technology solutions. The company's lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the primary and most aggressive form of brain cancer. Kazia Therapeutics Limited, formerly known as Novogen Limited, is based in Sydney, Australia.

Key Statistics

Overview:

Market Capitalization, $K 7,708
Enterprise Value, $K 7,038
Shares Outstanding, K 4,355
Annual Sales, $ 1,630 K
Annual Net Income, $ -17,560 K
Last Quarter Sales, $ 2,898 K
Last Quarter Net Income, $ -4,370 K
EBIT, $ 0 K
EBITDA, $ -17,430 K
60-Month Beta 1.98
% of Insider Shareholders 1.00%
% of Institutional Shareholders 30.89%
Float, K 4,311
% Float 99.00%
Short Volume Ratio 0.28

Growth:

1-Year Return -59.54%
3-Year Return -97.84%
5-Year Return -96.12%
5-Year Revenue Growth 45.54%
5-Year Earnings Growth 46.72%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 02/21/25
Earnings Per Share ttm 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 10/28/24

KZIA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % 0.00%
Profit Margin % -1,077.30%
Debt/Equity -0.06
Price/Sales 8.92
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -1.97
Interest Coverage -1.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar